[go: up one dir, main page]

DE60039863D1 - Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten - Google Patents

Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten

Info

Publication number
DE60039863D1
DE60039863D1 DE60039863T DE60039863T DE60039863D1 DE 60039863 D1 DE60039863 D1 DE 60039863D1 DE 60039863 T DE60039863 T DE 60039863T DE 60039863 T DE60039863 T DE 60039863T DE 60039863 D1 DE60039863 D1 DE 60039863D1
Authority
DE
Germany
Prior art keywords
immune responses
mitogens
cytokines
inhibition
pathological immune
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE60039863T
Other languages
English (en)
Inventor
David A Horwitz
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Application granted granted Critical
Publication of DE60039863D1 publication Critical patent/DE60039863D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/20—Cellular immunotherapy characterised by the effect or the function of the cells
    • A61K40/22—Immunosuppressive or immunotolerising
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/416—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/418—Antigens related to induction of tolerance to non-self
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/10—Growth factors
    • C12N2501/15—Transforming growth factor beta (TGF-β)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2501/00—Active agents used in cell culture processes, e.g. differentation
    • C12N2501/20—Cytokines; Chemokines
    • C12N2501/23—Interleukins [IL]

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Endocrinology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Dermatology (AREA)
  • Biochemistry (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Transplantation (AREA)
  • Pain & Pain Management (AREA)
  • Neurosurgery (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE60039863T 1999-05-05 2000-05-05 Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten Expired - Lifetime DE60039863D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US13261699P 1999-05-05 1999-05-05
PCT/US2000/012284 WO2000066158A2 (en) 1999-05-05 2000-05-05 Use of cytokines and mitogens to inhibit pathological immune responses

Publications (1)

Publication Number Publication Date
DE60039863D1 true DE60039863D1 (de) 2008-09-25

Family

ID=22454846

Family Applications (1)

Application Number Title Priority Date Filing Date
DE60039863T Expired - Lifetime DE60039863D1 (de) 1999-05-05 2000-05-05 Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten

Country Status (9)

Country Link
EP (1) EP1173549B1 (de)
JP (2) JP4132013B2 (de)
AT (1) ATE404662T1 (de)
AU (1) AU771080B2 (de)
CA (1) CA2372956A1 (de)
DE (1) DE60039863D1 (de)
DK (1) DK1173549T3 (de)
ES (1) ES2311462T3 (de)
WO (1) WO2000066158A2 (de)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6358506B1 (en) 1997-11-05 2002-03-19 University Of Southern California Use of cytokines and mitogens to inhibit pathological immune responses
US6803036B1 (en) 1998-03-03 2004-10-12 University Of Southern California Use of cytokines, cells and mitogens to inhibit graft versus host disease
EP1061949B1 (de) 1998-03-03 2009-07-15 University of Southern California Zytokinen und mitogenen um "graft-versus-host disease" zu verhindern
WO2001016296A2 (en) * 1999-09-01 2001-03-08 University Of Southern California Use of cytokines, cells, and mitogens to inhibit graft versus host disease
AU2001253400B2 (en) * 2000-04-11 2007-03-01 University Of Southern California A method to prevent graft rejection using tgf-beta to induce t suppressor cells
AU2003209755B2 (en) * 2002-02-06 2007-11-22 Ares Trading S.A. Tumor necrosis factor combined with interferon in demyelinating diseases
TW201733599A (zh) * 2016-02-17 2017-10-01 醫療法人社團滉志會 以發炎性疾病為對象之醫藥
US12458249B2 (en) * 2018-03-29 2025-11-04 Demao Yang Cell therapy for patients
EP4169524A1 (de) * 2021-10-25 2023-04-26 Ellennbe GmbH Immunmodulatorische substanz zur verwendung in einem verfahren zur behandlung und/oder prävention einer krankheit
EP4422671A1 (de) * 2021-10-25 2024-09-04 Ellennbe GmbH Pharmazeutische zusammensetzung und kit mit einer immunmodulatorischen substanz zur behandlung von krankheiten
WO2024084038A1 (en) * 2022-10-20 2024-04-25 Ellennbe Gmbh Platform technology for treatment of inflammatory, immunological and/or autoimmunological diseases

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1028738E (pt) * 1997-11-05 2003-08-29 Univ Southern California Utilizacao de citoquinas e mitogenios para inibir respostas imunitarias patologicas

Also Published As

Publication number Publication date
AU771080B2 (en) 2004-03-11
WO2000066158A2 (en) 2000-11-09
ATE404662T1 (de) 2008-08-15
EP1173549B1 (de) 2008-08-13
AU5587300A (en) 2000-11-17
EP1173549A2 (de) 2002-01-23
CA2372956A1 (en) 2000-11-09
WO2000066158A3 (en) 2001-02-15
ES2311462T3 (es) 2009-02-16
JP2008174564A (ja) 2008-07-31
JP4132013B2 (ja) 2008-08-13
DK1173549T3 (da) 2008-12-08
JP2002543152A (ja) 2002-12-17

Similar Documents

Publication Publication Date Title
DK1082410T3 (da) Humane CD45 - og/eller fibroblast mesenchymale stamceller
DE69828408D1 (de) Naphthyridinone zur hemmung der durch protein-tyrosin-kinase und zellzyklus kinase hervorgerufenen zellvermehrung
NZ334691A (en) Compositions of anti-4-1BB antibody effective for immunomodulation and treatment of T-cell autoimmune disease
DE60039863D1 (de) Verwendung von zytokinen und mitogenen zur inhibierung von pathologischen immunantworten
DK1226233T3 (da) Multipotente voksne stamceller og fremgangsmåder til isolering heraf
DE60020269D1 (de) Verwendung von interleukin-6 antagonisten zur behandlung von oestrogen-abhängigen krebs
ATE311853T1 (de) Verwendung von krillenzymen zur behandlung von zahnbelag
ATE331791T1 (de) Phosphodiesterase 10
FR2749022B1 (fr) Cellules aviaires immortelles
SE9502409D0 (sv) A process for in vitro analysis of toxic and allergenic substances
ATE321843T1 (de) Zellen, kulturverfahren, und ihre verwendung in autologer transplantationstherapie
ATE238061T1 (de) Verwendung von zytokinen und mitogenen für inhibierung von pathologischen immunantworten
DE69705936D1 (de) Teil der intronsequenz des von hippel-lindau(vhl)-gens und seine verwendung zur krankheitsdiagnose
ATE239781T1 (de) Immortalisierte menschliche prostata- epithelzellen und klone und ihre verwendungen zur untersuchung und therapie von prostata-krebs
WO2001042784A3 (en) Methods for screening compounds active on neurons
CA2517140A1 (en) Use of pc-cell derived growth factor (pcdgf) for increasing the proliferation of b cells
WO2002077178A3 (en) Method of screening for agents that regulate the shedding of membrane bound proteins and methods of use
DE60039517D1 (de) Verwendung eines ginkgo extraktes zur behandlung von krebs welcher durch überexpression von peripherem benzodiazepin rezeptor protein gekennzeichnet ist
DE60115039D1 (de) Screeningverfahren für modulatoren von methyltransferase abhängiger chromosomenstabilität
DE60020970D1 (de) Monoklonaler antikörper mit selektiver bindung an vgf und verwendung zur behandlung von vgf-erkrankungen
DE50009932D1 (de) Gentransfer in humane lymphocyten mittels retroviraler scfv-zelltargeting vektoren
DE60007864D1 (de) Verwendung von antileukoprotease zur behandlung von endometriose
AU2001295263A1 (en) Method of identifying abnormal immune reactions
DE69432517D1 (de) Verfahren zur vorhersage der effektivität der behandlung von tumoren durch in-vitro bestimmung der überlebens- und vermehrungsfähigkeit
AU4210900A (en) Products and methods for treating ptp lar related diseases

Legal Events

Date Code Title Description
8364 No opposition during term of opposition